Compared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

The FDA approved asundexian with antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.

Mona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.

Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.